JPWO2021167107A1 - - Google Patents
Info
- Publication number
- JPWO2021167107A1 JPWO2021167107A1 JP2022501104A JP2022501104A JPWO2021167107A1 JP WO2021167107 A1 JPWO2021167107 A1 JP WO2021167107A1 JP 2022501104 A JP2022501104 A JP 2022501104A JP 2022501104 A JP2022501104 A JP 2022501104A JP WO2021167107 A1 JPWO2021167107 A1 JP WO2021167107A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025197068A JP2026032056A (ja) | 2020-02-22 | 2025-11-17 | ヒトトランスフェリンレセプター結合ペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020028879 | 2020-02-22 | ||
| JP2020028879 | 2020-02-22 | ||
| PCT/JP2021/006709 WO2021167107A1 (ja) | 2020-02-22 | 2021-02-22 | ヒトトランスフェリンレセプター結合ペプチド |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025197068A Division JP2026032056A (ja) | 2020-02-22 | 2025-11-17 | ヒトトランスフェリンレセプター結合ペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021167107A1 true JPWO2021167107A1 (https=) | 2021-08-26 |
| JP7796636B2 JP7796636B2 (ja) | 2026-01-09 |
Family
ID=77390874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022501104A Active JP7796636B2 (ja) | 2020-02-22 | 2021-02-22 | ヒトトランスフェリンレセプター結合ペプチド |
| JP2025197068A Pending JP2026032056A (ja) | 2020-02-22 | 2025-11-17 | ヒトトランスフェリンレセプター結合ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025197068A Pending JP2026032056A (ja) | 2020-02-22 | 2025-11-17 | ヒトトランスフェリンレセプター結合ペプチド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230203098A1 (https=) |
| EP (1) | EP4108676A4 (https=) |
| JP (2) | JP7796636B2 (https=) |
| CN (1) | CN115151556A (https=) |
| AU (1) | AU2021224412A1 (https=) |
| CA (1) | CA3171988A1 (https=) |
| IL (1) | IL295797A (https=) |
| TW (1) | TW202140513A (https=) |
| WO (1) | WO2021167107A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117957240A (zh) * | 2021-08-19 | 2024-04-30 | 肽梦想株式会社 | 人转铁蛋白受体结合肽 |
| US20240390508A1 (en) * | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| WO2023027125A1 (ja) | 2021-08-24 | 2023-03-02 | ペプチドリーム株式会社 | ヒトトランスフェリンレセプター結合抗体－ペプチドコンジュゲート |
| EP4230638A1 (en) * | 2022-02-16 | 2023-08-23 | Lipotrue, S.L. | Peptides and compositions for use in cosmetics |
| AU2023331268A1 (en) | 2022-08-26 | 2025-03-06 | Peptidream Inc. | Cycloalkyne derivative |
| EP4626906A1 (en) * | 2022-11-29 | 2025-10-08 | Vacino Biotech Co., Ltd. | Transporter peptides and application thereof |
| TW202434613A (zh) * | 2023-02-17 | 2024-09-01 | 日商肽夢想股份有限公司 | 人類運鐵蛋白受體結合肽 |
| JPWO2024195710A1 (https=) * | 2023-03-17 | 2024-09-26 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05213996A (ja) * | 1991-10-11 | 1993-08-24 | F Hoffmann La Roche Ag | 血管作働性環状ペプチド |
| WO2012105595A1 (ja) * | 2011-02-02 | 2012-08-09 | 公益財団法人微生物化学研究会 | 血液脳関門を透過する薬物輸送体、ペプチド及びその用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60147718A (ja) | 1984-01-12 | 1985-08-03 | Seikosha Co Ltd | 太陽電池付きカラ−表示素子 |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| JPH06228199A (ja) | 1992-11-27 | 1994-08-16 | Takeda Chem Ind Ltd | 血液脳関門通過可能なペプチド結合体 |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| WO2007066627A1 (ja) | 2005-12-06 | 2007-06-14 | The University Of Tokyo | 多目的アシル化触媒とその用途 |
| BRPI1014253A2 (pt) * | 2009-07-02 | 2016-04-12 | Merz Pharma Gmbh & Co Kgaa | polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento |
| JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
| CA3092114A1 (en) | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| BR112014022435B1 (pt) * | 2012-03-21 | 2023-02-14 | Takeda Pharmaceutical Company Limited | Inibidores de tfpi e métodos de uso |
| HUE045144T2 (hu) | 2012-08-29 | 2019-12-30 | Hoffmann La Roche | Véragygát-shuttle |
| US20160068835A1 (en) | 2013-01-30 | 2016-03-10 | Peptidream Inc. | Flexible display method |
| CN103254280A (zh) * | 2013-03-07 | 2013-08-21 | 广州暨南大学医药生物技术研究开发中心 | 具有肿瘤细胞靶向结合能力的短肽及其应用 |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| CA3052936A1 (en) * | 2016-12-26 | 2018-07-05 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein of bdnf and anti-transferrin receptor antibody |
| IL276327B2 (en) | 2018-02-05 | 2024-05-01 | Japan Chem Res | Method for delivering drug to muscle |
-
2021
- 2021-02-22 WO PCT/JP2021/006709 patent/WO2021167107A1/ja not_active Ceased
- 2021-02-22 CA CA3171988A patent/CA3171988A1/en active Pending
- 2021-02-22 IL IL295797A patent/IL295797A/en unknown
- 2021-02-22 TW TW110106195A patent/TW202140513A/zh unknown
- 2021-02-22 JP JP2022501104A patent/JP7796636B2/ja active Active
- 2021-02-22 US US17/801,261 patent/US20230203098A1/en active Pending
- 2021-02-22 AU AU2021224412A patent/AU2021224412A1/en active Pending
- 2021-02-22 CN CN202180015934.0A patent/CN115151556A/zh active Pending
- 2021-02-22 EP EP21756644.7A patent/EP4108676A4/en active Pending
-
2025
- 2025-11-17 JP JP2025197068A patent/JP2026032056A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05213996A (ja) * | 1991-10-11 | 1993-08-24 | F Hoffmann La Roche Ag | 血管作働性環状ペプチド |
| WO2012105595A1 (ja) * | 2011-02-02 | 2012-08-09 | 公益財団法人微生物化学研究会 | 血液脳関門を透過する薬物輸送体、ペプチド及びその用途 |
Non-Patent Citations (1)
| Title |
|---|
| ZHANG, Y., ET AL.: "Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic e", DRUG DELIVERY, vol. 24, JPN6021016519, 2017, pages 1045 - 1055, ISSN: 0005743007 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230203098A1 (en) | 2023-06-29 |
| JP7796636B2 (ja) | 2026-01-09 |
| CN115151556A (zh) | 2022-10-04 |
| EP4108676A4 (en) | 2024-06-05 |
| EP4108676A1 (en) | 2022-12-28 |
| TW202140513A (zh) | 2021-11-01 |
| CA3171988A1 (en) | 2021-08-26 |
| IL295797A (en) | 2022-10-01 |
| AU2021224412A1 (en) | 2022-09-15 |
| JP2026032056A (ja) | 2026-02-25 |
| WO2021167107A1 (ja) | 2021-08-26 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20221012 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221018 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240131 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250128 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250326 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250523 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251203 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251209 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251223 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7796636 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |